NYSE:BSX - Boston Scientific Stock Price, News, & Analysis

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Boston Scientific Co. (NYSE:BSX) announced its quarterly earnings data on Wednesday, July, 25th. The medical equipment provider reported $0.41 EPS for the quarter, beating the Zacks' consensus estimate of $0.34 by $0.07. The medical equipment provider earned $2.49 billion during the quarter, compared to the consensus estimate of $2.47 billion. Boston Scientific had a net margin of 5.48% and a return on equity of 26.35%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share. View Boston Scientific's Earnings History.

Boston Scientific is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Boston Scientific.

Boston Scientific issued an update on its FY18 earnings guidance on Wednesday, July, 25th. The company provided earnings per share guidance of $1.37-1.41 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.39. The company issued revenue guidance of +8-9% to $9.80-9.88 billion, compared to the consensus revenue estimate of $9.82 billion.Boston Scientific also updated its Q3 guidance to $0.33-0.35 EPS.

22 Wall Street analysts have issued 12-month price objectives for Boston Scientific's shares. Their forecasts range from $27.00 to $43.00. On average, they expect Boston Scientific's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for Boston Scientific.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 16 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific.

Some companies that are related to Boston Scientific include 3M (MMM), Becton Dickinson and (BDX), Stryker (SYK), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Haemonetics (HAE), Globus Medical (GMED) and Insulet (PODD).

Press coverage about BSX stock has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Boston Scientific earned a coverage optimism score of 0.22 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 46.82 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Boston Scientific.

Boston Scientific's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (11.33%), BlackRock Inc. (7.91%), Janus Henderson Group PLC (3.02%), Bollard Group LLC (2.42%), Artisan Partners Limited Partnership (1.83%) and Bank of New York Mellon Corp (1.31%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

BSX stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Artisan Partners Limited Partnership, Voya Investment Management LLC, Bank of Montreal Can, Wells Fargo & Company MN, Bank of New York Mellon Corp, Orbimed Advisors LLC and OppenheimerFunds Inc.. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose and Timothy A Pratt. View Insider Buying and Selling for Boston Scientific.

BSX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Epoch Investment Partners Inc., BlackRock Inc., TD Asset Management Inc., Marshall Wace LLP, Putnam Investments LLC and First Quadrant L P CA. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BSX stock can currently be purchased for approximately $34.41.

Boston Scientific has a market capitalization of $46.40 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]